Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4472895 | 1.00 | GPBAR1 (0.32) | GPBAR1LMNASHBGSERPINA6CYP1A2 | |
| SCHEMBL5407826 | 1.00 | GPBAR1 (0.32) | GPBAR1LMNASHBGSERPINA6CYP1A2 | |
| SCHEMBL22986784 | 0.77 | DPP4 (0.30) | — | |
| SCHEMBL5868448 | 0.70 | LMNA (0.39) | GPBAR1LMNASHBGSERPINA6CYP1A2 | |
| SCHEMBL6847867 | 0.69 | SHBG (0.36) | GPBAR1LMNASHBGSERPINA6CYP1A2 | |
| SCHEMBL10260567 | 0.69 | SHBG (0.36) | GPBAR1LMNASHBGSERPINA6CYP1A2 | |
| SCHEMBL10261009 | 0.69 | SHBG (0.36) | GPBAR1LMNASHBGSERPINA6CYP1A2 | |
| SCHEMBL9290693 | 0.69 | SHBG (0.36) | GPBAR1LMNASHBGSERPINA6CYP1A2 | |
| SCHEMBL12304844 | 0.69 | SHBG (0.36) | GPBAR1LMNASHBGSERPINA6CYP1A2 | |
| SCHEMBL10292100 | 0.69 | SHBG (0.36) | GPBAR1LMNASHBGSERPINA6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | GPBAR1 758/4885LMNA 2226/4885SHBG 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.